# HaplnScience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/haplnscience

- Industry: Pharmaceuticals
- Headquarters: Seongnam, South Korea
- Website: www.haplnscience.com
- Total disclosed funding: $29M
- Latest round: Series B (Jan 19, 2021)
- Investors on record: 10

## About

HaplnScience, Inc., based in South Korea, specializes in developing innovative regenerative medicine therapies aimed at anti-aging and tissue regeneration, focusing on improving patient outcomes across various chronic conditions.HaplnScience, Inc. was founded in 2018 and operates out of Seongnam, South Korea. The company is engaged in creating advanced therapies for conditions such as chronic obstructive pulmonary disease (COPD) and osteoarthritis (OA). CEO Hubert Choi leads the company which has raised a total of KRW 22.7 billion in Series B funding as of January 19, 2021, with investors including Company K Partners and DSC Investment. The company has completed four deals to date, contributing to a current valuation of KRW 45 billion.HaplnScience specializes in advanced regenerative medicine therapies targeting anti-aging and tissue regeneration. Their product lineup includes HS-401 for COPD, HS-101 for osteoarthritis, HS-601 for dry eye disease, HS-201 for skin aging, and HS-301 addressing hair loss, utilizing unique delivery methods like inhalation and injections to enhance patient care. Their clientele includes healthcare providers, hospitals, and specialty clinics primarily across North America and Europe, responding to the demand for innovative therapeutic solutions.HaplnScience generates revenue through direct sales of its therapeutic products to healthcare institutions, supplemented by potential partnerships with pharmaceutical firms. The company handles bulk orders from medical facilities, supported by training for healthcare professionals. Pricing is determined by the complexity of therapies, ensuring tailored solutions for healthcare providers. Their flagship products, especially those for prevalent conditions like osteoarthritis and COPD, are expected to significantly contribute to revenue as they advance through clinical trials.In January 2021, HaplnScience, Inc. secured KRW 22.7 billion in Series B funding aimed at accelerating the development of new drugs. The company plans to introduce new products targeting unmet medical needs and is looking to expand into additional markets in North America and Europe by 2023. The funding will support the ongoing development and market introduction of therapies, enhancing their portfolio and addressing the rising demand for effective treatments.

## Funding rounds

- Series B, Jan 19, 2021, $21M — DSC Investment, JB Investment, Company K Partners, Albatross Investment, IBK Capital, STIC Ventures, Lifecore Partners
- Series A, Jul 12, 2019, $8.5M — DSC Investment, Company K Partners, Korea Technology Finance Corporation
- Seed, Feb 1, 2019 — Bluepoint Partners, Korea Tech Incubator for Startup
- Seed, Jan 1, 2019 — Bluepoint Partners

## Investors

- Bluepoint Partners (https://capitalatlas.ai/funds/bluepoint-partners) — Seed
- Korea Tech Incubator for Startup — Seed
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A, Series B
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series A, Series B
- Korea Technology Finance Corporation — Series A
- JB Investment (https://capitalatlas.ai/funds/jb-investment) — Series B
- Albatross Investment (https://capitalatlas.ai/funds/albatross-investment) — Series B
- IBK Capital (https://capitalatlas.ai/funds/ibk-capital) — Series B
- STIC Ventures (https://capitalatlas.ai/funds/stic-ventures) — Series B
- Lifecore Partners — Series B